Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis

References

• Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 2016. doi:10.1093/neuonc/nov189
   Google Scholar
• Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med. 2013;369:1561–1563. doi:10.1056/NEJMcibr130940224131182
   PubMed Web of Science ®Google Scholar
• Walid M. Prognostic factors for long-term survival after glioblastoma. Perm J. 2008;12. doi:10.7812/TPP/08-027.
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Dennis EA, Deems RA, Yu L. Extracellular phospholipase A2. Adv Exp Med Biol. 1992;318:35–39.1636503
   PubMedGoogle Scholar
• Murakami M, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: an update. Biochimie. 2013. doi:10.1016/j.biochi.2012.09.007
   PubMed Web of Science ®Google Scholar
• Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006;79:1–33. doi:10.1016/j.prostaglandins.2005.10.00516516807
   PubMed Web of Science ®Google Scholar
• Cummings BS. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol. 2007;74:949–959. doi:10.1016/j.bcp.2007.04.02117531957
   PubMed Web of Science ®Google Scholar
• Mounier CM, Wendum D, Greenspan E, Fléjou JF, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: SPLA2-III as a biomarker candidate. Br J Cancer. 2008;98:587–595. doi:10.1038/sj.bjc.660418418212756
   PubMed Web of Science ®Google Scholar
• Sved P, Scott KF, McLeod D, et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 2004;64:6934–6940. doi:10.1158/0008-5472.CAN-03-301815466184
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Chedid M, et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res. 2001;7(12):3857–3861.
   Web of Science ®Google Scholar
• Menschikowski M, Hagelgans A, Nacke B, et al. Epigenetic control of group V phospholipase A2 expression in human malignant cells. Tumor Biol. 2016;37:8097–8105. doi:10.1007/s13277-015-4670-x
   PubMedGoogle Scholar
• Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2. J Biol Chem. 2005;280:24987–24998. doi:10.1074/jbc.M50208820015863501
   PubMed Web of Science ®Google Scholar
• Smith MW, Yue ZN, Geiss GK, et al. Identification of novel tumor markers in hepatitis C Virus-associated hepatocellular carcinoma. Cancer Res. 2003;63(4):859–864.
   Web of Science ®Google Scholar
• Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005;46:1249–1257. doi:10.1016/j.jacc.2005.06.05616198839
   PubMed Web of Science ®Google Scholar
• Wootton PTE, Drenos F, Cooper JA, et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet. 2006;15:355–361. doi:10.1093/hmg/ddi45316368710
   PubMed Web of Science ®Google Scholar
• Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today. 2003;8:710–716. doi:10.1016/S1359-6446(03)02754-512927514
   PubMed Web of Science ®Google Scholar
• Rodrigues RS, Izidoro LF, de Oliveira RJJ, Sampaio SV, Soares AM, Rodrigues VM. Snake venom phospholipases A2: a new class of antitumor agents. Protein Pept Lett. 2009;16:894–898. doi:10.2174/09298660978892326619689415
   PubMed Web of Science ®Google Scholar
• Henderson WR, Chi EY, Bollinger JG, et al. Importance of group X–secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med. 2007;204:865–877. doi:10.1084/jem.2007002917403936
   PubMed Web of Science ®Google Scholar
• Sadaria MR, Meng X, Fullerton DA, et al. Secretory phospholipase A2 inhibition attenuates intercellular adhesion molecule-1 expression in human esophageal adenocarcinoma cells. Ann Thorac Surg. 2011;91:1539–1545. doi:10.1016/j.athoracsur.2011.01.01721396625
   PubMed Web of Science ®Google Scholar
• Wang M, Hao FY, Wang JG, Xiao W. Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer. Eur Rev Med Pharmacol Sci. 2014;18(18):2648–2654.
   Web of Science ®Google Scholar
• Dong Z, Meller J, Succop P, et al. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells. Int J Oncol. 2014;45(3):978–984. doi:10.3892/ijo.2014.248624913497
   PubMed Web of Science ®Google Scholar
• Martín R, Cordova C, Gutiérrez B, Hernández M, Nieto ML. A dangerous liaison: leptin and sPLA2-IIA join forces to induce proliferation and migration of astrocytoma cells. PLoS One. 2017. doi:10.1371/journal.pone.0170675
   Web of Science ®Google Scholar
• Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101:293–299. doi:10.1111/j.1349-7006.2009.01419.x19961486
   PubMed Web of Science ®Google Scholar
• Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131–138. doi:10.1016/j.canlet.2012.12.01023268331
   PubMed Web of Science ®Google Scholar
• Martinez-Orozco R, Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Perez Salazar E. Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A. Eur J Cell Biol. 2010;89:476–488. doi:10.1016/j.ejcb.2009.12.00520207443
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Y, Weng J, et al. Decrease of lactogenic hormones induce epithelial-mesenchymal transition via TGFβ1 and arachidonic acid during mammary gland involution. J Reprod Dev. 2017;63(3):325–332. doi:10.1262/jrd.2016-15728381667
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. doi:10.1126/science.116438218772396
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. doi:10.1056/NEJMoa080871019228619
   PubMed Web of Science ®Google Scholar